Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? (Q33830080)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Laura De Giglio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Giovanna Borriello

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Laura Leonardi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Valeria Barletta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Carlo Pozzilli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

25 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1186/1471-2377-11-26

23 January 2020

exact match

0 references

cites work

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Defining the clinical course of multiple sclerosis: Results of an international survey

4 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

4 July 2018

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058026

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

4 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Interferon beta in relapsing–remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-26

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

21 January 2018

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

12 December 2020

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-11-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

23 January 2020

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-11-26

9 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21352517%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference